DOCSLIB.ORG

Composition and Antiviral Activity of Substituted

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Composition and Antiviral Activity of Substituted (19) TZZ_¥¥Z_T (11) EP 1 363 705 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: A61P 31/18 (2006.01) A61P 31/12 (2006.01) 13.06.2012 Bulletin 2012/24 A61K 31/496 (2006.01) A61K 31/501 (2006.01) A61K 31/53 (2006.01) A61K 31/506 (2006.01) (2006.01) (2006.01) (21) Application number: 02707413.7 C07D 401/14 C07D 403/14 C07D 241/02 (2006.01) C07D 253/08 (2006.01) C07D 251/02 (2006.01) C07D 241/36 (2006.01) (22) Date of filing: 02.01.2002 C07D 471/02 (2006.01) (86) International application number: PCT/US2002/000455 (87) International publication number: WO 2002/062423 (15.08.2002 Gazette 2002/33) (54) COMPOSITION AND ANTIVIRAL ACTIVITY OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES ZUSAMMENSETZUNG UND ANTIVIRALE WIRKUNG SUBSTITUIERTER AZAINDOLOXOESSIGSÄUREPIPERAZIN- DERIVATIVE COMPOSITION ET ACTIVITE ANTIVIRALE DE DERIVES DE PIPERAZINE AZAINDOLEOXOACETIQUE SUBSTITUES (84) Designated Contracting States: • KADOW, John, F. AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU Wallingford, CT 06492 (US) MC NL PT SE TR • YIN, Zhiwei Designated Extension States: Meriden, CT 06450 (US) AL LT LV MK RO SI (74) Representative: Reitstötter - Kinzebach (30) Priority: 02.02.2001 US 266183 P Patentanwälte 23.08.2001 US 314406 P Postfach 86 06 49 81633 München (DE) (43) Date of publication of application: 26.11.2003 Bulletin 2003/48 (56) References cited: WO-A1-00/76521 WO-A1-01/62255 (73) Proprietor: Bristol-Myers Squibb Company WO-A1-02/04440 WO-A1-96/11929 Princeton NJ 08543-4000 (US) • WANG TAO ET AL: "Discovery of 4-benzoyl-1-[(4- (72) Inventors: methoxy-1H- pyrrolo[2,3-b]pyridin-3-yl)o • WANG, Tao xoacetyl]-2- (R)-methylpiperazine (BMS-378806): Middletown, CT 06457 (US) a novel HIV-1 attachment inhibitor that interferes • ZHANG, Zhongxing with CD4-gp120 interactions." JOURNAL OF Madison, CT 06443 (US) MEDICINAL CHEMISTRY 25 SEP 2003, vol. 46, no. • MEANWELL, Nicholas, A. 20, 25 September 2003 (2003-09-25), pages East Hampton, CT 06424 (US) 4236-4239, XP002533377 ISSN: 0022-2623 Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention). EP 1 363 705 B1 Printed by Jouve, 75001 PARIS (FR) EP 1 363 705 B1 Description REFERENCE TO RELATED APPLICATIONS 5 [0001] This application claims the benefit of U.S. Provisional Application Serial Numbers 60/314,406 filed August 23, 2001 and 60/266,183 filed February 2, 2001. BACKGROUND OF THE INVENTION 10 Field of the Invention [0002] This invention provides compounds having drug and bio-affecting properties, their pharmaceutical compositions and method of use. In particular, the invention is concerned with azaindole piperazine diamide derivatives that possess unique antiviral activity. More particularly, the present invention relates to compounds useful for the treatment of HIV 15 and AIDS. Background Art [0003] HIV-1 (human immunodeficiency virus -1) infection remains a major medical problem, with an estimated 33.6 20 million people infected worldwide. The number of cases of HIV and AIDS (acquired immunodeficiency syndrome) has risen rapidly. In 1999, 5.6 million new infections were reported, and 2.6 million people died from AIDS. Currently available drugs for the treatment of HIV include six nucleoside reverse transcriptase (RT) inhibitors (zidovudine, didanosine, stavudine, lamivudine, zalcitabine and abacavir), three non-nucleoside reverse transcriptase inhibitors (nevirapine, de- lavirdine and efavirenz), and six peptidomimetic protease inhibitors (saquinavir, indinavir, ritonavir, nelfinavir, amprenavir 25 and lopinavir). Each of these drugs can only transiently restrain viral replication if used alone. However, when used in combination, these drugs have a profound effect on viremia and disease progression. In fact, significant reductions in death rates among AIDS patients have been recently documented as a consequence of the widespread application of combination therapy. However, despite these impressive results, 30 to 50% of patients ultimately fail combination drug therapies. Insufficient drug potency, non-compliance, restricted tissue penetration and drug-specific limitations within 30 certain cell types (e.g. most nucleoside analogs cannot be phosphorylated in resting cells) may account for the incomplete suppression of sensitive viruses. Furthermore, the high replication rate and rapid turnover of HIV-1 combined with the frequent incorporation of mutations, leads to the appearance of drug-resistant variants and treatment failures when sub- optimal drug concentrations are present (Larder and Kemp; Gulick; Kuritzkes; Morris-Jones et al; Schinazi et al; Vacca and Condra; Flexner; Berkhout and Ren et al; (Ref. 6-14)). Therefore, novel anti-HIV agents exhibiting distinct resistance 35 patterns, and favorable pharmacokinetic as well as safety profiles are needed to provide more treatment options. [0004] Currently marketed HIV-1 drugs are dominated by either nucleoside reverse transcriptase inhibitors or pepti- domimetic protease inhibitors. Non-nucleoside reverse transcriptase inhibitors (NNRTIs) have recently gained an in- creasingly important role in the therapy of HIV infections (Pedersen & Pedersen, Ref 15). At least 30 different classes of NNRTI have been described in the literature (De Clercq, Ref. 16) and several NNRTIs have been evaluated in clinical 40 trials. Dipyridodiazepinone (nevirapine), benzoxazinone (efavirenz) and bis(heteroaryl) piperazine derivatives (delavir- dine) have been approved for clinical use. However, the major drawback to the development and application of NNRTIs is the propensity for rapid emergence of drug resistant strains, both in tissue cell culture and in treated individuals, particularly those subject to monotherapy. As a consequence, there is considerable interest in the identification of NNRTIs less prone to the development of resistance (Pedersen & Pedersen, Ref 15). 45 [0005] Several indole derivatives including indole-3-sulfones, piperazino indoles, pyrazino indoles, and 5H-indolo[3,2- b][1,5]benzothiazepine derivatives have been reported as HIV-1 reverse transciptase inhibitors (Greenlee et al, Ref. 1; Williams et al, Ref. 2; Romero et al, Ref. 3; Font et al, Ref. 17; Romero et al, Ref. 18; Young et al, Ref. 19; Genin et al, Ref. 20; Silvestri et al, Ref. 21). Indole 2-carboxamides have also been described as inhibitors of cell adhesion and HIV infection (Boschelli et al, US 5,424,329, Ref. 4). Finally, 3-substituted indole natural products (Semicochliodinol A and 50 B, didemethylasterriquinone and isocochliodinol) were disclosed as inhibitors of HIV-1 protease (Fredenhagen et al, Ref. 22). Other indole derivatives exhibiting antiviral activity useful for treating HIV are disclosed in PCT WO 00/76521 (Ref. 93). Also, indole derivatives are disclosed in PCT WO 00/71535 (Ref. 94). [0006] Structurally related aza-indole amide derivatives have been disclosed previously (Kato et al, Ref. 23; Levacher et al, Ref. 24; Dompe Spa, WO-09504742, Ref. 5(a); SmithKline Beecham PLC, WO-09611929, Ref. 5(b); Schering 55 Corp., US-05023265, Ref. 5(c)). However, these structures differ from those claimed herein in that they are aza-indole mono-amide rather than unsymmetrical aza-indole piperazine diamide derivatives, and there is no mention of the use of these compounds for treating viral infections, particularly HIV. Other azaindoles have been also disclosed by Wang et al, Ref. 95. Nothing in these references can be construed to disclose or suggest the novel compounds of this invention 2 EP 1 363 705 B1 and their use to inhibit HIV infection. REFERENCES CITED 5 Patent documents [0007] 1. Greenlee, W.J.; Srinivasan, P.C. Indole reverse transcriptase inhibitors. U.S. Patent 5,124,327. 10 2. Williams, T.M.; Ciccarone, T.M.; Saari, W. S.; Wai, J.S.; Greenlee, W.J.; Balani, S.K.; Goldman, M.E.; Theohrides, A.D. Indoles as inhibitors of HIV reverse transcriptase. European Patent 530907. 3. Romero, D.L.; Thomas, R.C.; Preparation of substituted indoles as anti-AIDS pharmaceuticals. PCT WO 93 15 /01181. 4. Boschelli, D.H.; Connor, D.T.; Unangst, P.C. Indole-2-carboxamides as inhibitors of cell adhesion. U.S. Patent 5,424,329. 20 5. (a) Mantovanini, M.; Melillo, G.; Daffonchio, L. Tropyl 7-azaindol-3-ylcarboxyamides as antitussive agents. PCT WO 95/04742 (Dompe Spa). (b) Cassidy, F.; Hughes, I.; Rahman, S.; Hunter, D. J. Bisheteroaryl-carbonyl and carboxamide derivatives with 5HT 2C/2B antagonists activity. PCT WO 96/11929. (c) Scherlock, M. H.; Tom, W. C. Substituted 1H-pyrrolopyridine-3-carboxamides. U. S. Patent 5,023,265. 25 Other Publications [0008] 6. Larder, B.A.; Kemp, S.D. Multiple mutations in the HIV-1 reverse transcriptase confer high-level resistance to 30 zidovudine (AZT). Science, 1989, 246,1155-1158. 7. Gulick, R.M. Current antiretroviral therapy: An overview. Quality of Life Research, 1997, 6, 471-474. 8. Kuritzkes, D.R. HIV resistance to current therapies. Antiviral Therapy, 1997, 2 (Supplement 3), 61-67. 35 9. Morris-Jones, S.; Moyle, G.; Easterbrook, P.J. Antiretroviral therapies in HIV-1 infection. Expert Opinion on Investigational Drugs, 1997, 6(8),1049-1061. 10. Schinazi, R.F.; Larder, B.A.; Mellors, J.W. Mutations in retroviral genes associated with drug resistance. Inter- 40 national Antiviral News, 1997, 5,129-142,. 11. Vacca, J.P.; Condra, J.H. Clinically effective HIV-1 protease inhibitors. Drug Discovery Today, 1997, 2, 261-272. 12. Flexner, D. HIV-protease inhibitors. Drug Therapy, 1998, 338, 1281-1292. 45 13. Berkhout, B. HIV-1 evolution under pressure of protease inhibitors: Climbing the stairs of viral fitness. J. Biomed. Sci., 1999, 6, 298-305. 14. Ren, S.; Lien, E.
Load more

Recommended publications
  • WO 2013/079708 Al 6 June 2013 (06.06.2013) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2013/079708 Al 6 June 2013 (06.06.2013) P O P C T (51) International Patent Classification: Limited, Jealott's Hill International Research Centre, A01N 43/14 (2006.01) C07D 215/227 (2006.01) Bracknell Berkshire RG42 6EY (GB). C07D 309/06 (2006.01) C07C 49/747 (2006.01) (74) Agents: SYNGENTA LIMITED et al; Intellectual Prop (21) International Application Number: erty Department, Syngenta Limited, P.O. Box 3538, PCT/EP20 12/074 172 Jealott's Hill International Research Centre, Bracknell Berkshire RG42 6YA (GB). (22) International Filing Date: 30 November 2012 (30.1 1.2012) (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, (25) Filing Language: English AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, (26) Publication Language: English BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (30) Priority Data: HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, 3448/DEL/201 1 30 November 201 1 (30. 11.201 1) IN KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, (71) Applicants (for all designated States except US): SYN- ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, GENTA LIMITED [GB/GB]; European Regional Centre, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, Priestley Road, Surrey Research Park, Guildford Surrey RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, GU2 7YH (GB).
    [Show full text]
  • Spectroscopic, Electronic, and Mechanistic Studies of Silicon Surfaces Chemically Modified with Short Alkyl Chains
    Spectroscopic, Electronic, and Mechanistic Studies of Silicon Surfaces Chemically Modified with Short Alkyl Chains Thesis by Noah Thomas Plymale In Partial Fulfillment of the Requirements for the degree of Doctor of Philosophy CALIFORNIA INSTITUTE OF TECHNOLOGY Pasadena, California 2017 (Defended 17 October, 2016) ii © 2016 Noah Thomas Plymale ORCID: 0000-0003-2564-8009 iii ACKNOWLEDGEMENTS As I am finishing writing this thesis and reflecting on the past ~5 years in graduate school, I am really overwhelmed with the quality of people with whom I have worked. First, I have to acknowledge my advisor Nate Lewis for working with me on some really interesting surface chemistry and giving me the chance to guide my own projects throughout graduate school. Over the years, I have developed a profound appreciation for Nate and the way he runs his research group. We are all lucky to be able to make our own mistakes, forge our own path, and build our own futures under the guidance of one of the world’s most well-known and respected chemists. Thank you, Nate, for everything you have done for me! I have been lucky enough to have one of the most experienced and supportive committees possible in graduate school. Bill Goddard has been supportive and provided valuable advice during committee meetings and exams. Thank you, Bill, for working with me though this process! Harry Gray served as the chair of my committee, and has been incredibly encouraging throughout graduate school. Through the National Science Foundation Center for Chemical Innovation: Solar Fuels program, I have had the fantastic opportunity of working with Harry on outreach programs like Juice from Juice.
    [Show full text]
  • Reactions of Organosilylmetallic Compounds with Some Halides Dan Kazumi Aoki Iowa State University
    Iowa State University Capstones, Theses and Retrospective Theses and Dissertations Dissertations 1961 Reactions of organosilylmetallic compounds with some halides Dan Kazumi Aoki Iowa State University Follow this and additional works at: https://lib.dr.iastate.edu/rtd Part of the Organic Chemistry Commons Recommended Citation Aoki, Dan Kazumi, "Reactions of organosilylmetallic compounds with some halides " (1961). Retrospective Theses and Dissertations. 1958. https://lib.dr.iastate.edu/rtd/1958 This Dissertation is brought to you for free and open access by the Iowa State University Capstones, Theses and Dissertations at Iowa State University Digital Repository. It has been accepted for inclusion in Retrospective Theses and Dissertations by an authorized administrator of Iowa State University Digital Repository. For more information, please contact [email protected]. REACTIONS OF ORGANOSIIHMETAL1ZC COMPOUNDS WITH SOME HAHDES by Dan Kazumi Aok± A Dissertation Submitted to the Graduate Faculty in Partial Fulfillment of The Requirements for the Degree of DOCTOR OF PHIIOSOPHY Major Subject: Organic Chemistry Approved: Signature was redacted for privacy. In Chargé of lfe.jor.Mbrk Signature was redacted for privacy. Head of Major Depa: Signature was redacted for privacy. Iowa State University Of Science and Technology Ames, Iowa 1961 il TABLE OF CONTENTS _. - Page I. INTRODUCTION 1 II. HISTORICAL 3 A. Reactions of Grignard Reagents with Organic Halldes 3 B. Reactions of Organblithlum Compounds with Organic Halldes 9 I# The condensation reaction 10 2. The halogen-metal interconversion reaction - 11 3» The metalation reaction 16 G# Reactions of R3EIA Compounds with Organic Halldes 20 le Reactions of tripheqylsilyllithium with aryl halldes 20 2. Reactions of triphenylgermyl 11 thium with organic halldes 20 3# Reactions of triaryl- and trialkyltin-lithium with organic halldes 21 Reactions of trlphenyllead-llthium with organic halldes 23 HI.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2015/0342185 A1 Mound Et Al
    US 20150342185A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2015/0342185 A1 Mound et al. (43) Pub. Date: Dec. 3, 2015 (54) HERBICIDALLY ACTIVECYCLIC DIONE C07D 309/32 (2006.01) COMPOUNDS, ORDERIVATIVES C07D 213/50 (2006.01) THEREFOR, SUBSTITUTED BY A PHENYL (52) U.S. Cl. WHICH HAS ANALKYNYL-CONTAINING CPC .............. A0IN 43/16 (2013.01); C07D 309/32 SUBSTITUENT (2013.01); C07C 49/747 (2013.01); A0IN 35/06 (2013.01); C07D 309/06 (2013.01); (71) Applicant: Syngenta Limited, Guildford Surrey C07D 213/50 (2013.01); A0IN 43/40 (CH) (2013.01); C07D 311/96 (2013.01); C07C 321/20 (2013.01); C07C329/06 (2013.01); (72) Inventors: William Roderick Mound, Bracknell A0IN 47/06 (2013.01); C07C 2102/44 Berkshire (GB); James Nicholas Scutt, (2013.01) Bracknell Berkshire (GB); Mark Slater, Bracknell Berkshire (GB); Nigel James (57) ABSTRACT Willetts, Bracknell Berkshire (GB) The present invention relates to a compound of formula (I), (73) Assignee: Syngenta Limited, Guildford Surrey wherein: X is methyl orchlorine; R is methyl or chlorine; R. (CH) is hydrogen, methyl, ethyl, n-propyl, cyclopropyl, vinyl, ethynyl, fluorine, chlorine, bromine, C-Calkoxy, C-C- (21) Appl. No.: 14/653,674 fluoroalkoxy, C-Calkoxy-C-Calkoxy- O C fluoroalkoxy-C-Calkoxy-; and Y is O, S, S(O), S(O), (22) PCT Filed: Dec. 19, 2013 N(C-C alkyl), N(C-Calkoxy), C(O), CRR or CR'R''CR'R' ; and G, R, R, R and R are as (86). PCT No.: PCT/EP2013/077541 defined herein; wherein the compound of formula (I) is optionally present as an agrochemically acceptable salt S371 (c)(1), thereof.
    [Show full text]
  • Information to Users
    INFORMATION TO USERS This manuscript has been reproduced from the microfilm master. U M I films the text directly from the original or copy submitted. Thus, some thesis and dissertation copies are in typewriter 6ce, while others may be from any type o f computer printer. The quality of this reproduction is dependent upon the quality of the copy suhmitted. Broken or indistinct print, colored or poor quality illustrations and photographs, print bleedthrough, substandard margins, and improper alignment can adversely affect reproduction. In the unlikely event that the author did not send U M I a complete manuscript and there are missing pages, these will be noted. Also, if unauthorized copyright material had to be removed, a note will indicate the deletion. Oversize materials (e.g., maps, drawings, charts) are reproduced by sectioning the original, beginning at the upper left-hand comer and continuing from left to right in equal sections with small overlaps. Each original is also photographed in one exposure and is included in reduced form at the back o f the book. Photographs included in the original manuscript have been reproduced xerographically in this copy. Higher quality 6” x 9” black and white photographic prints are available for any photographs or illustrations appearing in this copy for an additional charge. Contact U M I directly to order. UMI A Bell & Howell Infonnadon Company 300 North Zeeb Road, Ann Arbor MI 48106-1346 USA 313/761-4700 800/521-0600 TANDEM REACTIONS OF FUNCTIONALIZED SOUARATE ESTERS AND OTHER CYCLOBUTENEDIONES. METHODOLOGY AND APPLICATIONS TO THE SYNTHESIS OF POLYQUINANE NATURAL PRODUCTS DISSERTATION Presented in Partial Fulfillment of the Requirements for the Degree Doctor of Philosophy in the Graduate School of The Ohio State University by Tina M.
    [Show full text]